Aktienanalyse zu VOGX (VOGX)

$31.730

-0.416 (-1.31%)Zum Schluss

Loading chart…

High: 34.000
Open: 32.120
VWAP: 32.45
Vol: 89.62K
Mkt Cap: —
Low: 31.630
Amount: 2.91M
EV/EBITDA, TTM: 0.00

Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The Company's primary objective is to advance its lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome, or GDCS. Mizagliflozin is a selective inhibitor of SGLT1, a glucose transporter present in the gastrointestinal tract responsible for transporting dietary glucose into the bloodstream. Its VGX-2857 is a novel small molecule-based product candidate that is orally available. VGX-2857 is a combination of two novel small molecules that have demonstrated the potential to aid in weight loss in one fixed dosage form.

AI analysis of VOGX (VOGX)

buy

Vogenx, Inc. is a good buy right now due to its significant upside potential indicated by analyst price targets of $42 and $55, which represent a potential increase of 32.4% and 73.5% from the current price of $31.73. The company is positioned in a niche market with its Phase 2b-ready oral SGLT1 inhibitor, mizagliflozin, which addresses a $2 billion opportunity in the U.S. with no current FDA-approved treatments. However, the forward P/E ratio is 0, indicating uncertainty in earnings, which is a risk to consider.

Bewertungskennzahlen

The current forward P/E ratio for VOGX (VOGX) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E

Current P/E

0.00

Forward EV/EBITDA

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Forward P/S

5Y Average P/S

Current P/S

0.00

Event-Zeitleiste

2026-08-17 (ET)